Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.69 |
| ▸ | POLB | P06746 | 10/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.69 |
| ▸ | CBFB | Q13951 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 9/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426699 | 0.99 | MAPT (0.68) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL432032 | 0.97 | MAPT (0.65) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14955151 | 0.89 | MAPT (0.67) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL192254 | 0.89 | MAPT (0.55) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL193464 | 0.88 | MAPT (0.55) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL426856 | 0.88 | MAPT (0.54) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL427190 | 0.88 | MAPT (0.54) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14954879 | 0.87 | MAPT (0.55) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL18537618 | 0.87 | MAPT (0.64) | MAPTPOLBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14955058 | 0.86 | NPC1 (0.52) | MAPTPOLBSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | claimed |
| US-12528805-B2 | Solid forms of emetine | ACER THERAPEUTICS INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12223145-B2 | Movement control apparatus and movable body | Sony Group Corporation (JP) | 2025-02-11 | — | — | US | disclosed |
| US-12197552-B2 | Authentication device and authentication system | KABUSHIKI KAISHA TOSHIBA (JP) | 2025-01-14 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240228485-A1 | SOLID FORMS OF EMETINE | ACER THERAPEUTICS INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024075848-A1 | SERVER DEVICE CONTROL METHOD | パナソニックオートモーティブシステムズ株式会社 | 2024-04-11 | — | — | WO | disclosed |
| US-11884663-B2 | Solid forms of emetine | ACER THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240006672-A1 | BATTERY DISCHARGE APPARATUS AND DISCHARGING METHOD THEREOF | MAROO ON INC. (KR) | 2024-01-04 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2400845-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 138/4885POLB 4109/4885SMN1; SMN2 993/4885 |
| US-20240228485-A1 | SOLID FORMS OF EMETINE | EML4, EIF4A2, SFPQ | MAPT 324/4885POLB 2684/4885SMN1; SMN2 1618/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | MAPT 85/4885POLB 4278/4885SMN1; SMN2 1076/4885 |
| US-12528805-B2 | Solid forms of emetine | TPMT, EML4, HLA-DRB1 | MAPT 7/4885POLB 3474/4885SMN1; SMN2 86/4885 |
| US-11884663-B2 | Solid forms of emetine | EML4, EIF4A2, SFPQ | MAPT 324/4885POLB 2684/4885SMN1; SMN2 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.